Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at ...
CARDIOTTRansform missed its primary endpoint, but its secondary analysis of eplontersen in ATTR-CM patients on background ...
Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its ...
FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS ...
Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for ...
A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring ...
How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing ...
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial data.
MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal ...
SOC vs RES is decided cell by cell in the visit grid, not procedure by procedure. Here is what that means when an auditor ...
AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.
Caliway's Phase 3 SUPREME-01 trial for CBL-514 now enrolling patients. The pivotal study evaluates abdominal fat reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results